Mr. Hendrick spent over 20 years working for Genzyme Corporation, most recently as the Vice President and General Manager of Early Development for the Oncology business. He has served as an advisor to Cetya since August 2013 and as its CEO and a member of its Board of Directors since July 2014. He also served on the Management Advisory Board of Signet Laboratories prior to its acquisition by Covance in 2007. Mr. Hendrick worked for Integrated Genetics for six years prior to its merger with Genzyme in 1989 and in research for the Life Sciences division of Millipore Corporation for 11 years before joining Integrated Genetics and the biotechnology industry in 1983. Mr. Hendrick holds a B.S. in Life Sciences from the Massachusetts Institute of Technology and an M.B.A. from Northeastern University.